Regional Adipose Tissue Hormone/Cytokine Production Before and After Weight Loss in Abdominally Obese Women

Tongjian You1, Xuewen Wang2, Karin M. Murphy3, Mary F. Lyles3, Jamehl L. Demons3, Rongze Yang4, Da-Wei Gong4,5 and Barbara J. Nicklas3

Objective: To compare the regional differences in subcutaneous adipose tissue hormone/cytokine production in abdominally obese women during weight loss.

Methods: Forty-two abdominally obese, older women underwent a 20-week weight loss intervention composed of hypocaloric diet with or without aerobic exercise (total energy expenditure: ~2800 kcal/week). Subcutaneous (gluteal and abdominal) adipose tissue biopsies were conducted before and after the intervention. Adipose tissue gene expression and release of leptin, adiponectin, and interleukin 6 (IL-6) were determined.

Results: The intervention resulted in significant weight loss (−10.1 ± 0.7 kg, P < 0.001). At baseline, gene expression of adiponectin were higher (P < 0.01), and gene expression and release of IL-6 were lower (both P < 0.05) in abdominal than in gluteal adipose tissue. After intervention, leptin gene expression and release were lower in both gluteal and abdominal adipose tissue compared to baseline (P < 0.05-0.01). Abdominal, but not gluteal, adipose tissue adiponectin gene expression and release increased after intervention (both P < 0.05).

Conclusion: A 20-week weight loss program decreased leptin production in both gluteal and abdominal adipose tissue, but only increased adiponectin production from abdominal adipose tissue in obese women. This depot-specific effect may be of importance for the treatment of health complications associated with abdominal adiposity.

Obesity (2014) 22, 1679–1684. doi:10.1002/oby.20743

Introduction

Adipose tissue expresses and releases a number of hormones and cytokines, such as leptin, adiponectin, and interleukin 6 (IL-6), which are important factors in the regulation of energy intake and inflammatory responses (1). Leptin is an adipose-derived hormone that regulates energy intake and expenditure by inhibiting appetite and altering energy metabolism (2). Adiponectin is an adipose-derived protein that acts as an anti-inflammatory agent and an insulin sensitizer (2,3). IL-6 is released mostly by nonfat cells within adipose tissue (4) and plays an important role in promoting local and systemic inflammatory reactions (5).

Obesity is a major risk factor for cardiovascular disease and diabetes (6,7). Circulating levels of leptin and IL-6 levels are elevated, and levels of adiponectin are lower, in obese, compared to nonobese, individuals (8). Abdominal obesity is an independent metabolic risk factor (9). In our previous study, insulin resistance and glucose intolerance were related to abdominal, adipose tissue IL-6, and adiponectin gene expression in abdominally obese, older women (10). These findings indicate that regional adipose tissue hormone/cytokine production may play an important role in mechanisms of metabolic complications associated with abdominal obesity.

Recent studies indicate that genes involved in inflammatory responses and metabolism are differently expressed in abdominal and lower-body adipose tissue (11), and developmentally programmed differences may contribute to the distinct phenotypic characteristics of peripheral fat in women (12). In abdominally obese...
women, abdominal adipose tissue, compared to lower body adipose tissue (i.e. gluteal adipose tissue), may have more active metabolic properties (13) and may respond differently to weight loss. However, the depot differences in adipose tissue hormone/cytokine production in response to weight loss are still not known in this specific population that has elevated metabolic risk.

Therefore, the purpose of this study was to investigate: (1) whether there were differences between abdominal and gluteal subcutaneous adipose tissue leptin, adiponectin, and IL-6 production in abdominally obese older women; and (2) whether there were depot differences in the response of subcutaneous adipose tissue leptin, adiponectin, and IL-6 production to weight loss by diet and exercise.

Methods

Subjects

Participants \( (n = 42) \) in this study were from a subset of 112 women who were recruited for a larger trial, and main study results were previously published (14). Primary inclusion/exclusion criteria were: (1) overweight or obese (BMI = 25-40 kg/m²) and abdominally obese (waist girth > 88 cm), (2) middle-aged or older (age = 50-70 years) and postmenopausal (at least one year without menses), (3) nonsmoking, (4) not on hormone replacement therapy, (5) sedentary (< 15 min of exercise, 2 times/week) in the past 6 months, and (6) weight-stable (< 5% weight change) for at least 6 months.

The initial screening included a medical history review, physical examination, fasting blood profile (lipoprotein lipids and glucose), and 12-lead resting electrocardiogram. Women were also excluded if they had: (1) untreated hypertension (blood pressure > 160/90 mmHg), (2) hypertriglyceridemia (triglycerides > 400 mg/dl), (3) insulin-dependent diabetes, (4) active cancer, or (5) liver, renal, or hematological disease. All women also underwent a graded exercise test to exclude those with an abnormal cardiovascular response to exercise.

The study was approved by the Wake Forest University Institutional Review Board for Human Research. All women signed informed consent to participate in the study.

Weight loss intervention

All women underwent 20 weeks of intervention composed of hypo-caloric diet with or without aerobic exercise. The diet intervention was comprised providing the participants with lunch and supper meals prepared by the Wake Forest University General Clinical Research Center metabolic kitchen staff. The women purchased and prepared their breakfast meal, in consultation with a registered dietitian. Women were allowed to consume non-caloric, non-caffeinated beverages and were provided with a daily calcium supplement (1000 mg/day). A subset of the women \( (n = 28) \) also walked on a treadmill at moderate to vigorous intensity, for 30-55 min each day, 3 days/week. The total calorie/energy deficit was adjusted to be ~2800 kcal/week, and the average daily calorie intake recorded by all women was 99% of the provided calorie level. All measures were collected before and after the 20-week intervention.

Body composition

Height and weight were measured to calculate BMI (kg/m²). Waist and hip circumferences were measured by a tape measure. Fat mass and percent body fat were measured by dual energy X-ray absorptiometry (Hologic Delphi QDR, Bedford, MA). Visceral and subcutaneous adipose tissue volumes around the abdomen were measured by a four-slice multidetector computed tomography system (GE Medical Systems, Milwaukee, WI).

Blood measures

Blood samples were collected in EDTA-treated vacutainers via venipuncture in the early morning after an overnight fast. The samples were centrifuged at 4°C for 20 min, and plasma was separated and stored at ~70°C until analysis. Plasma triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured by standardized hospital laboratory procedures. Plasma concentrations of leptin, adiponectin, and IL-6 were measured by enzyme-linked immunosorbent assay using Quantikine kits (R&D Systems, Minneapolis, MN).

Oral glucose tolerance test

After an overnight fast, a 20-gauge polyethylene catheter was placed in an antecubital vein for blood sampling. Blood samples were drawn at different time points before (10 and 0 min) and after (30, 60, 90, and 120 min) a 75-g glucose ingestion for the determination of plasma glucose and insulin. Plasma glucose was measured with the glucose hexokinase method (Bayer Diagnostics, Tarrytown, NY). Plasma insulin was determined by a chemiluminescent immunoassay (Siemens, Malvern, PA). The estimate of insulin sensitivity by homeostasis model assessment (HOMA) score was calculated with the following formula: fasting plasma insulin (U/ml) \( \times \) glucose (mmol/l) / 22.5, which is equal to fasting insulin (pmol/l) \( \times \) glucose (mg/dl) 2.815 after unit conversions (15). Glucose and insulin areas during OGTT were determined with Taí’s model: 1/2 \( \times \) \( \sum \) insulin + glucose concentrations at the different time points (16).

Adipose tissue leptin, adiponectin, and IL-6 production

Subcutaneous (abdominal and gluteal) adipose tissue biopsies were conducted under local anesthesia (1% lidocaine) after an overnight fast. Adipocyte size was determined as previously described (17). Adipose tissue mRNA was extracted, and reverse transcription (RT) was performed by using the Advantage RT-for-PCR Kit (Clontech, Palo Alto, CA); real-time quantification of target gene (leptin, adiponectin, and IL-6) to \( \beta \)-actin mRNA was performed, using ABI Taqman gene expression assay kits on an ABI PRISM 7900 Sequence Detection System (Applied Biosystems, Foster City, CA) (10). Adipose tissue in vitro hormone/cytokine release was processed in a subset of these 42 subjects as previously described (4), and levels of leptin, adiponectin, and IL-6 in the release media were determined by using the Milliplex immunoassay (Millipore, St. Charles, MO).

Statistical analyses

Data analyses were performed using IBM SPSS Statistics 20 (Armonk, NY). For variables that were not normally distributed, the logarithm of each was used for parametric statistical analyses. Changes in variables were calculated by using postintervention minus pre-intervention values. We did not see an exercise effect on changes in metabolic and hormone/cytokine variables; therefore, the following analyses were performed in the whole cohort. Paired t-
tests were used to compare pre- and post-intervention values on all variables, and depot differences (abdominal vs. gluteal) on adipose tissue variables. Pearson’s correlation was used for analysis of relationships between changes in variables. All data are presented as mean ± standard error, and the level of significance was set at $P < 0.05$ for all analyses.

**Results**

**Participant characteristics, body composition, and metabolic variables**

For all 42 participants, mean age was 58 ± 1 years and mean postmenopausal time was 13 ± 2 years; 45% of the women were African American.

Body composition variables before and after the intervention are shown in Table 1. At baseline, adipocyte size was significantly larger in gluteal than in abdominal adipose tissue ($P < 0.01$). The 20-week intervention resulted in significant weight loss (−10.1 ± 0.7 kg, −1.2 to −20.3 kg; −11.5 ± 0.8%, −1.4% to −22.9%), and decreased fat mass, percent body fat, waist circumference, hip circumference, waist-to-hip ratio, abdominal and gluteal subcutaneous adipocyte size, and abdominal subcutaneous and visceral fat volumes ($P < 0.01$).

Metabolic variables before and after the intervention are shown in Table 2. The intervention reduced triglyceride levels ($P < 0.05$), but did not change levels of total cholesterol, HDL-C, and LDL-C. The intervention significantly reduced fasting glucose, glucose area, fasting insulin, insulin area, and HOMA index ($P < 0.05$), and tended to lower 2-hour glucose and 2-hour insulin during the OGTT test ($P = 0.07$ and 0.16, respectively).

**Circulating levels of leptin, adiponectin, and IL-6**

Circulating levels of leptin, adiponectin, and IL-6 before and after the intervention are shown in Table 3. The intervention reduced circulating levels of leptin ($P < 0.001$), and IL-6 ($P < 0.05$), and increased circulating adiponectin levels ($P < 0.05$).

**Abdominal and gluteal subcutaneous adipose tissue leptin, adiponectin, and IL-6 production**

Gluteal and abdominal adipose tissue gene expression and release levels of leptin, adiponectin, and IL-6 before the intervention are shown in Table 4. At baseline, gene expression of adiponectin was higher ($P < 0.01$), and gene expression and release of IL-6 were lower (both $P < 0.05$) in abdominal than in gluteal adipose tissue. There were no depot differences in gene expression and release of leptin and release of adiponectin at baseline.

As shown in Figure 1, the weight loss intervention decreased leptin gene expression and release levels in both gluteal and abdominal adipose tissue ($P < 0.05$-$0.01$). As shown in Figure 2, the intervention increased abdominal adipose tissue adiponectin gene expression and release (both $P < 0.05$), but did not change gluteal adiponectin production. The intervention did not alter gluteal and abdominal adipose tissue IL-6 production as indicated in Figure 3.

**Relationship between changes in adipose tissue production of leptin, adiponectin, and IL-6 and changes in body composition and metabolic variables**

Over the 20-week weight loss intervention, there were no significant correlations between changes in adipose tissue gene expression or release levels of leptin, adiponectin, and IL-6 and changes in their respective circulating levels. However, changes in abdominal leptin gene expression were positively related to changes in subcutaneous abdominal adipose tissue volume ($r = 0.48, P < 0.01$). Additionally, changes in gluteal leptin gene expression were positively related to plasma LDL-C levels ($r = 0.43, P < 0.05$), and were negatively related to HDL-C levels ($r = -0.43, P < 0.05$). Changes in abdominal adiponectin gene expression were negatively related to changes in 2-hour glucose levels during OGTT ($r = -0.40, P < 0.05$). In both gluteal and abdominal adipose tissue, changes in IL-6 gene expression were positively related to changes in fasting glucose, glucose area, fasting insulin, and insulin area ($P < 0.001$-$0.05$), and tended to lower 2-hour glucose and 2-hour insulin during the OGTT test ($P = 0.07$ and 0.16, respectively).

**Table 2: Circulating metabolic risk factors before and after the 20-week diet and exercise intervention**

| Variable                  | Pre-intervention | Post-intervention |
|---------------------------|------------------|-------------------|
| Triglycerides (mg/dl)     | 125.5 ± 8.7      | 108.6 ± 6.5*      |
| Total cholesterol (mg/dl) | 193.1 ± 4.8      | 186.8 ± 4.4       |
| HDL cholesterol (mg/dl)   | 49.5 ± 1.8       | 50.4 ± 1.6        |
| LDL cholesterol (mg/dl)   | 118.5 ± 4.5      | 115.3 ± 4.1       |
| Fasting glucose (mg/dl)   | 96.7 ± 1.7       | 92.5 ± 1.6*       |
| 2-hour glucose (mg/dl)    | 137.4 ± 7.9      | 122.7 ± 5.1       |
| Glucose area (mg/dl/2h)   | 17483 ± 633      | 15644 ± 479***    |
| Fasting insulin (pmol/l)  | 64.1 ± 5.0       | 46.8 ± 5.4**      |
| 2-hour insulin (pmol/l)   | 516.2 ± 64.5     | 440.5 ± 53.5      |
| Insulin area (pmol/l/2h)  | 52864 ± 4590     | 42277 ± 3638*     |
| HOMA index                | 2.25 ± 0.20      | 1.57 ± 0.20**     |

All data are means ± SE. N = 42. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$ compared with baseline.
TABLE 3 Circulating hormones and cytokines before and after the 20-week weight loss intervention

|                      | Pre-intervention | Post-intervention |
|----------------------|------------------|-------------------|
| Leptin (ng/ml)       | 38.0 ± 2.9       | 21.0 ± 2.2***     |
| Adiponectin (μg/ml)  | 7.93 ± 0.62      | 9.34 ± 0.79*      |
| IL-6 (pg/ml)         | 2.93 ± 0.31      | 2.39 ± 0.27*      |

All data are means ± SE. N=42. *P < 0.05, **P < 0.01, ***P < 0.001 compared with baseline.

were positively related to changes in glucose area during OGTT (r = 0.67, P < 0.01 and r = 0.46, P < 0.05, respectively).

Discussion

This study compared the regional differences in subcutaneous adipose tissue leptin, adiponectin, and IL-6 production in abdominally obese women before and after weight loss. Our findings surprisingly support that adiponectin gene expression was higher, and IL-6 gene expression and release were lower, in abdominal than in gluteal adipose tissue. Additionally, weight loss reduced both abdominal and gluteal adipose tissue leptin gene expression and release, but preferentially increased abdominal adipose tissue adiponectin gene expression and release in these women.

Similar to our findings, in a recent study, contrary to the authors’ original hypothesis, gluteal subcutaneous adipose tissue had a greater inflammatory gene expression profile than abdominal subcutaneous adipose tissue (18). The authors questioned about the protective nature of gluteo-femoral fat. In our current study, we did see a significant larger fat cell size in the gluteal than abdominal adipose tissue, and this could be the reason why abdominal adipose tissue has higher adiponectin expression and lower IL-6 production. Based on our previous report, circulating metabolic risk factors are related to abdominal adipose tissue cytokines (10); therefore, the location of adipose tissue, but not the absolute expression or release levels of hormones and cytokines from local adipose tissue, may play a more important role in the regulating mechanism of metabolic syndrome.

TABLE 4 Gluteal and abdominal adipose tissue hormones and cytokines before the 20-week weight loss intervention

|                      | Gluteal          | Abdominal         |
|----------------------|------------------|-------------------|
| Leptin gene expression (leptin/β-actin) | 0.19 ± 0.02      | 0.20 ± 0.03       |
| Leptin release (ng/ml) | 0.81 ± 0.08      | 0.68 ± 0.06       |
| Adiponectin gene expression (adiponectin/β-actin) | 2.79 ± 0.22      | 3.55 ± 0.21**     |
| Adiponectin release (ng/ml) | 76.2 ± 3.7       | 69.5 ± 5.1        |
| IL-6 gene expression (IL-6/β-actin) | 0.0033 ± 0.0008  | 0.0020 ± 0.0005*  |
| IL-6 release (ng/ml) | 0.70 ± 0.10      | 0.48 ± 0.07*      |

All data are means ± SE. N = 42 for hormone/cytokine gene expression and N=27 for hormone/cytokine release. *P < 0.05, **P < 0.01 compared with gluteal fat depot.

Our findings that weight loss reduced adipose tissue leptin gene expression and release are supported by previous weight loss intervention studies (19,20). However, none of these studies measured leptin production in different fat depots. Our study is the first one to report that weight loss reduced leptin expression and release levels in both abdominal and gluteal adipose tissue in obese individuals. Interestingly, we observed that weight loss only altered abdominal, but not gluteal, adipose tissue adiponectin gene expression and release levels in these abdominally obese women. Several previous studies reported that hypocaloric diet did not alter abdominal subcutaneous adipose tissue adiponectin gene expression in obese subjects (21-23), and one study reported that adiponectin gene expression in subcutaneous adipose tissue of obese women responds rapidly to short-term very low calorie diet (24). Our findings that weight loss increased abdominal adipose tissue adiponectin production are similar to those in previous weight loss studies involving both diet and exercise interventions. For example, weight loss by diet and exercise reduced adipose tissue inflammation, determined from an increased mRNA expression of adiponectin and a decreased expression of pro-inflammatory cytokines (25,26). Another interesting finding of our study is that change in a metabolic variable (glucose intolerance) was related to change in abdominal, but not gluteal adipose tissue adiponectin gene expression. These differences could be because of more active metabolic properties (e.g. higher blood flow rate and temperature) of the abdominal adipose tissue compared to the gluteal adipose tissue in abdominally obese women (13).

We did not see a significant reduction in IL-6 production from abdominal and gluteal adipose tissue in older women following weight loss. Similarly, short-term to medium-term weight loss by hypocaloric diet...
with or without exercise did not alter IL-6 gene expression in abdominal adipose tissue in obese individuals (23,26). However, very low calorie diet for 3-10 weeks reduced IL-6 levels in adipose tissue of obese women (19,21). Moreover, excessive weight loss by laparoscopic adjustable gastric banding significantly reduced subcutaneous adipose tissue IL-6 gene expression in severely obese patients (27). Interestingly, a recent study reported that a dietary weight loss program composed of 1 month of very low calorie diet, 2 months of low calorie diet, and 3 months of weight maintenance, lowered IL-6 gene expression in abdominal, but not gluteal adipose tissue in obese postmenopausal women (28). It is possible that the approach and magnitude of weight loss are important factors for these significant findings.

In the current study, we did not see any significant correlations between changes in adipose tissue hormone/cytokine production and changes in their circulating levels over the 20-week intervention. Adipose tissue is an endocrine organ with regional variations in metabolic properties (29). As we only collected subcutaneous adipose tissue, it is possible that weight loss affected hormone/cytokine production in other adipose tissue regions (e.g. visceral fat and intra-muscular fat) more than subcutaneous fat. Additionally, although adipose tissue is a major organ to release these hormones/cytokines into the circulation, there are other tissues and cells (e.g. endothelial cells and innate immune cells) that also contribute to the altered circulating levels in obesity and in response to weight loss (30).

The mechanisms through which weight loss altered adiponectin production in abdominal adipose tissue are still unclear. A recent study reported that diet and exercise shifted the adiponectin multimer distribution towards a lower molecular weight and increased the number of anti-inflammatory macrophages, and tended to decrease the number of pro-inflammatory macrophages in subcutaneous abdominal adipose tissue (31). Additionally, only whole adipose tissue samples were processed and analyzed for cytokine/hormone production in the current study. It would be helpful to understand the mechanisms of adipose tissue metabolism if cytokine/hormone production could be measured in isolated adipocytes and stromal vascular cells within adipose tissue (4).

In conclusion, weight loss by hypocaloric diet and aerobic exercise reduces leptin gene expression and release in both gluteal and abdominal adipose tissue, but only increases adiponectin gene expression and release from abdominal adipose tissue in abdominally obese women. Considering the role of abdominal adipose tissue adiponectin in regulating metabolic function, this depot-specific effect may be of importance for the treatment of health complications associated with abdominal adiposity. Further studies will need to focus on the mechanisms through which weight loss alters regional adipose tissue hormones/cytokines and the related changes in metabolic function in obese individuals. Moreover, similar studies are also needed to be completed in other subgroups, such as individuals with gluteofemoral obesity.

Acknowledgments
We thank the study coordinators, nurses, lab technicians, and exercise physiologists for their assistance, and thank all the subjects for their participation in the study.
References

1. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-2556.
2. Fortuno A, Rodriguez A, Gomez-Ambrosi J, Frühbeck G, Diez J. Adipose tissue as an endocrine organ: Role of leptin and adiponectin in the pathogenesis of cardiovascular diseases. J Physiol Biochem 2003;59:51-60.
3. Haluzik M, Parizkova J, Haluzik MM. Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res 2004;53:123-129.
4. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847-850.
5. Eder K, Baféty N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res 2009;58:727-736.
6. Marinou K, Tousoulis D, Antonopoulos AS, Stefanadi E, Stefanadis C. Obesity and cardiovascular disease: From pathophysiology to risk stratification. Int J Cardiol 2010;138:3-8.
7. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999;282:1523-1529.
8. Derosa G, Fogari E, D’Angelo A, et al. Adipocytokine Levels in Obese and Non-Obese Subjects: An Observational Study. Inflammation 2013;36:914-920.
9. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881-887.
10. You T, Yang R, Lyles MF, Gong D, Nicklas BJ. Abdominal adipose tissue cytokine gene expression: Relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab 2005;288:E741-E747.
11. Rehner CW, Karimpour-Fard A, Hernandez TL, et al. Regional differences in subcutaneous adipose tissue gene expression. Obesity 2012;20:2168-2173.
12. Karastergiou K, Fried SK, Xie H, et al. Distinct developmental signatures of human abdominal and gluteal subcutaneous adipose tissue depots. J Clin Endocrinol Metab 2013;98:362-371.
13. Tan GD, Goossens GH, Humphreys SM, Vidal H, Karpe F. Upper and lower body adipose tissue function: A direct comparison of fat mobilization in humans. Obes Res 2004;12:114-118.
14. Nicklas BJ, Wang X, You T, et al. Effect of exercise intensity on abdominal fat loss during calorie restriction in overweight and obese postmenopausal women: A randomized, controlled trial. Am J Clin Nutr 2009;89:1043-1052.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
16. Tai MM. A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care 1994;17:152-154.
17. You T, Murphy KM, Lyles MF, Demons RL, Lenchik L, Nicklas BJ. Addition of aerobic exercise to dietary weight loss preferentially reduces abdominal adipocyte size. Int J Obes (Lond) 2006;30:1211-1216.
18. Evans J, Goeadeke JH, Soderstrom I, et al. Depot- and ethnic-specific differences in the relationship between adipose tissue inflammation and insulin sensitivity. Clin Endocrinol (Oxf) 2011;74:51-59.
19. Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000;85:3338-3342.
20. Viguerie N, Vidal H, Arner P, et al. Adipose tissue gene expression in obese subjects during low-fat and high-fat hypocaloric diets. Diabetologia 2005;48:123-131.
21. Arvidsson E, Viguerie N, Andersson I, Verdich C, LANGIN D, Arner P. Effects of different hypocaloric diets on protein secretion from adipose tissue of obese women. Diabetes 2004;53:1966-1971.
22. Behre CJ, Gummesson A, Jernas M, et al. Dissociation between adipose tissue expression and serum levels of adiponectin during and after diet-induced weight loss in obese women with and without the metabolic syndrome. Diabetes 2013;62:1022-1028.
23. Salas-Salvado J, Bulló M, Garcia-Lordá P, et al. Subcutaneous adipose tissue cytokine production is not responsible for the restoration of systemic inflammatory markers during weight loss. Int J Obes (Lond) 2006;30:1714-1720.
24. Liu YM, Lacorte JM, Viguerie N, et al. Adiponectin gene expression in subcutaneous adipose tissue of obese women in response to short-term very low calorie diet and refeeding. J Clin Endocrinol Metab 2003;88:5881-5886.
25. Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab 2006;290:E961-967.
26. Christiansen T, Paulsen SK, Bruun JM, Ploug T, Pedersen SB, Richelsen B. Diet-induced weight loss and exercise alone and in combination enhance the expression of adiponectin receptors in adipose tissue and skeletal muscle, but only diet-induced weight loss enhanced circulating adiponectin. J Clin Endocrinol Metab 2010;95:911-919.
27. Moschen AR, Molnar C, Geiger S, et al. Anti-inflammatory effects of excessive weight loss: Potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 2010;59:1259-1264.
28. Malisova L, Rossmeslova L, Kovacova Z, et al. Expression of inflammation-related genes in gluteal and abdominal subcutaneous adipose tissue during weight-reducing dietary intervention in obese women. Physiol Res 2013.
29. Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: Implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med 2013;34:1-11.
30. You T, Arsenis NC, Disanzo BL, Lamonte MJ. Effects of exercise training on chronic inflammation in obesity: Current evidence and potential mechanisms. Sports Med 2013;43:243-256.
31. Aaerbach P, Nordby P, Bendtsen LQ, et al. Differential effects of endurance training on weight loss in plasma adiponectin multimers and adipose tissue macrophages in younger, moderately overweight men. Am J Physiol Regul Integr Comp Physiol 2013.